Previsão

Comprar	0
Manter	5
Vender	0

Notícias Ir para o feed de notícias

Silverback Therapeutics hits 52-week high after strong price surge

Shares of Silverback Therapeutics reached a new 52-week high at $18.59, marking a year-over-year increase of 112.46%. The biotechnology company is benefiting from investor optimism, progress in its clinical pipeline, and a solid financial position. Analysts see further upside potential, while the company's market capitalization now stands at $1.81 billion. » Mais em de.investing.com
Safety Shot completes acquisition of Yerbae Brands and expands product portfolio

Safety Shot, Inc. has completed the acquisition of Yerbae Brands Corp. through a court-approved plan of arrangement. Following the transaction, Safety Shot shareholders hold approximately 81.64% and former Yerbae shareholders about 18.36% of the merged company. Safety Shot also plans to expand its product portfolio to include nootropics and sleep aids, and has entered into a debt settlement agreement with Silverback Capital Corporation. » Mais em de.investing.com

Dados financeiros da empresa

No último trimestre, SILVERBACK THERAP. -,0001 Aktie registou receitas de € 29,49 mi e um ganho líquido de -€ 54,62 mi

(EUR)	junho de 2026	YoY
Receitas	29,49 mi	121,16%
Ganho bruto	0	-
Ganho líquido	-54,62 mi	43,44%
EBITDA	-53,86 mi	42,32%

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 477,21 mi
Número de ações	93,77 mi
Máximo/mínimo de 52 semanas	€ 6,54 - € 2,43
Dividendos	Não
Beta	0,00
PER (PE Ratio)	-2,06
PEG (PEG Ratio)	0,02
P/VC (PB Ratio)	35,72
P/V (PS Ratio)	3,82

Perfil da empresa

Silverback Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen, das gewebebezogene Therapeutika für die Behandlung von chronischen Virusinfektionen, Krebs und anderen schweren Krankheiten entwickelt. Das Unternehmen bietet SBT8230 zur Behandlung chronischer Hepatitis-B-Virusinfektionen an, indem es eine antivirale Immunantwort durch gezielte TLR8-Aktivierung in der Leber auslöst. Silverback Therapeutics, Inc. wurde im Jahr 2016 gegründet und hat seinen Hauptsitz in Seattle, Washington.

Nome	SILVERBACK THERAP. -,0001 Aktie
CEO	Peter A. Thompson
Sede	Seattle, wa EUA
Site	silverbacktx.com
Setor	Materiais básicos
Indústria	Produtos químicos
Entrada em bolsa	03/12/2020
Colaboradores	90